Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial-Reference-Cited by-同舟云学术

Evaluation of the effect of sodium–glucose co‐transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR‐Reduced trial

Published:2019-07-16 Issue:10 Volume:21 Page:1270-1278
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Packer Milton¹²,Butler Javed³,Filippatos Gerasimos S.⁴⁵,Jamal Waheed⁶,Salsali Afshin⁷,Schnee Janet⁷,Kimura Karen⁸,Zeller Cordula⁹,George Jyothis⁶,Brueckmann Martina⁶¹⁰,Anker Stefan D.¹¹,Zannad Faiez¹²,Packer Milton,Anker Stefan D.,Butler Javed,Filippatos Gerasimos,Zannad Faiez,George Jyothis,Brueckmann Martina,Perrone Sergio,Nicholls Stephen,Janssens Stefan,Bocchi Edmar,Giannetti Nadia,Verma Subodh,Jian Zhang,Spinar Jindrich,Seronde Marie‐France,Böhm Michael,Merkely Bela,Chopra Vijay,Senni Michele,Taddei Stefano,Tsutsui Hiroyuki,Choi Dong‐Ju,Chuquiure Eduardo,La Rocca Hans Pieter Brunner,Ponikowski Piotr,Juanatey Jose Ramon Gonzalez,Squire Iain,Butler Javed,Januzzi James,Pina Ileana,Pocock Stuart J.,Carson Peter,Doehner Wolfram,Miller Alan,Haas Markus,Pehrson Steen,Komajda Michel,Anand Inder,Teerlink John,Rabinstein Alejandro,Steiner Thorsten,Kamel Hooman,Tsivgoulis Georgios,Lewis James,Freston James,Kaplowitz Neil,Mann Johannes,Petrie Mark,Bernstein Richard,Cheung Alfred,Green Jennifer,Januzzi James,Kaul Sanjay,Ping Carolyn Lam Su,Lip Gregory,Marx Nikolaus,McCullough Peter,Mehta Cyrus,Ponikowski Piotr,Rosenstock Julio,Sattar Naveed,Scirica Benjamin,Tsutsui Hiroyuki,Verma Subodh,Wanner Christoph,Welty Francine K.,Parhofer Klaus G.,Clayton Tim,Pedersen Terje R.,Lees Kennedy R.,Konstam Marvin A.,Greenberg Barry,Palmer Mike, , , , , , ,

Affiliation:

1. Baylor Heart and Vascular Institute Baylor University Medical Center Dallas TX USA

2. Imperial College London UK

3. University of Mississippi School of Medicine Jackson MI USA

4. Department of Cardiology National and Kapodistrian University of Athens Athens Greece

5. School of Medicine Athens University Hospital Attikon Athens Greece

6. Boehringer Ingelheim International GmbH Ingelheim Germany

7. Boehringer Ingelheim Pharmaceuticals Ridgefield CT USA

8. Boehringer Ingelheim Canada Ltd. Burlington Canada

9. Boehringer Ingelheim Pharma GmbH & Co. KG Biberach Germany

10. Faculty of Medicine Mannheim University of Heidelberg Mannheim Germany

11. Department of Cardiology (CVK); and Berlin Institute of Health Center for Regenerative Therapies (BCRT); German Centre for Cardiovascular Research (DZHK) partner site, Berlin, Germany Charité Universitätsmedizin Berlin Berlin Germany

12. Inserm INI‐CRCT, CHRU Université de Lorraine Nancy France

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ejhf.1536

Reference36 articles.

1. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

3. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

4. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

5. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME®trial

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of glycaemic status on the cardiac effects of empagliflozin when initiated immediately after myocardial infarction: A post‐hoc analysis of the EMMY trial;Diabetes, Obesity and Metabolism;2024-01-29

2. The role and application of current pharmacological management in patients with advanced heart failure;Heart Failure Reviews;2024-01-29

3. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF;JACC: Heart Failure;2024-01

4. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial;Journal of Cardiac Failure;2023-10

5. SGLT2 inhibitors: an evidence-based update on cardiovascular implications;Expert Opinion on Investigational Drugs;2023-09-02